Skip to search formSkip to main contentSkip to account menu

EPZ-6438

Known as: E7438, EPZ6438 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

BenzamidesPyridonesTazemetostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
18F-Labeled PET Probe Targeting Enhancer of Zeste Homologue 2 (EZH2) for Cancer Imaging.
The enzyme enhancer of zeste homologue 2 (EZH2) plays a catalytic role in histone methylation (H3K27me3), one of the epigenetic… 
2019
2019
Abstract C55: Mapping the pharmacotranscriptomic landscape of pancreatic circulating tumor cell organoids
Introduction: Pancreatic cancer is characterized by early metastasis and resistance to chemotherapy. To elucidate the… 
2018
2018
A személyre szabott terápia új lehetősége follicularis lymphomában – Az EZH2 hiszton metil-transzferáz gátlása
Absztrakt: A follicularis lymphoma terapiajaban a rituximab alkalmazasanak koszonhetően a betegek varhato elettartama szamottev… 
2017
2017
Chromatin biology: Breaking into the PRC2 cage.
New small-molecule inhibitors of the histone methyltransferase PRC2 interfere with the allosteric activation of enzymatic… 
2015
2015
302 A phase 1 study of EPZ-6438 (E7438), an Enhancer of Zeste-Homolog 2 (EZH2) inhibitor: Preliminary activity in INI1-negative tumors
2015
2015
Abstract B6: Advanced image analysis of H3K27 trimethylation in skin from subjects dosed with the EZH2 inhibitor tazemetostat
Tazemetostat (EPZ-6438 or E7438) is a selective small molecule inhibitor of the enhancer of zeste homolog 2 (EZH2) histone… 
Review
2014
Review
2014
MYELOID NEOPLASIA shRNA screening identi fi es JMJD 1 C as being required for leukemia maintenance
Translocations involvingmixed lineage leukemia (MLL) gene occur frequently in acute leukemia, especially in childhood and… 
2014
2014
277 The discovery and pre-clinical development of the first clinical stage EZH2-inhibitor, EPZ-6438 (E7438)
2014
2014
Mutant Non-Hodgkin Lymphoma EZH 2 Activity in Selective Inhibition of EZH 2 by EPZ-6438 Leads to Potent Antitumor
Mutationswithin the catalytic domain of the histonemethyltransferase EZH2havebeen identified in subsets of patients with non… 
2012
2012
Preclinical Characterization of E7438, a Potent, Selective Inhibitor of Protein Methyltransferase EZH2 with Robust Antitumor Activity Against EZH2 Mutated Non-Hodgkin Lymphoma Xenografts in Mice
Abstract 3712 The coupled enzymatic activity of wild-type and mutant EZH2 results in hyper-trimethylation of histone H3 lysine… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)